Event

Steven J. Pascoe

MBBSM MS
GSK

MeiLan K. Han

MD, MS
Univ Michigan Hlth Care System;University of Michigan;University of Michigan Health System;University of Michigan School of Medicine;University of Michigan, Ann Arbor

David Lomas

PhD, FRCP
University College London

Maggie Tabberer

MSc
GSK

Robert A. Wise

MD
Johns Hopkins Bayview;Johns Hopkins Medicine;Johns Hopkins Univ;Johns Hopkins University;Johns Hopkins University School of Medicine

Fernando J. Martinez

MD, MS
Cornell University;New York-Presbyterian Hospital/Weill Cornell Medical Center;Weill Cornell Medical College;Weill Cornell Medical College, Cornell University;Weill Cornell Medicine

Gerard J. Criner

MD
Lewis Katz School of Medicine at Temple University;Lewis Katz School of Medicine at Temple University, Temple University Hospital;Temple Univ Hosp;Temple Univ Hospital;Temple University;Temple Univers

Mark T. Dransfield

MD
Lung Health Center, University of Alabama at Birmingham;UAB;Univ of Alabama Birmingham;Univ of Alabama Birmingham & Birmingham VA Med Ctr;Univ of Alabama Birmingham & Birmingham VA Med Ctr;Un

David M. G. Halpin

PhD
Royal Devon and Exeter Hospital;Royal Devon and Exeter Hospital, University of Exeter Medical School

Jean Brooks

MSc
GSK

Noushin Brealey

MRCGP MSc
GSK

C Elaine Jones

PhD
GSK

Sally Kilbride

MSc
GSK

Dave Singh

MD, NP
Manchester Academic Health Science Centre, The University of Manchester;Medicines Evaluation Unit (MEU), University of South Manchester NHS Foundation Trust;The University of Manchester, University Ho

Peter Lange

MD
University of Copenhagen

Nicola C. Day

PhD
GSK

Frank Barnhart

D.V.M.
GSK

David A. Lipson

MD
GlaxoSmithKline;GSK;GSK and Perelman School of Medicine, University of Pennsylvania

Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial